AbbVie's Allergan Aesthetics division has filed three material events with the SEC (April 29, May 12, and June 22, 2026), each flagged as potentially significant to investors. While the specific details of these 8-K filings are not yet public, the timing and frequency suggest material changes to pricing, rebate structures, or Allē loyalty program terms—the three levers that directly impact per-unit toxin and per-syringe filler economics for independent practices.